Coadministration of milk thistle and indinavir in healthy subjects

被引:68
作者
DiCenzo, R
Shelton, M
Jordan, K
Koval, C
Forrest, A
Reichman, R
Morse, G
机构
[1] Univ Rochester, Med Ctr, Dept Med, Infect Dis Unit, Rochester, NY 14642 USA
[2] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 07期
关键词
D O I
10.1592/phco.23.7.866.32723
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To determine if milk thistle (silymarin) alters the pharmacokinetics of indinavir. Design. Sequential crossover trial. Setting. General clinical research center. Subjects. Ten healthy subjects. Intervention. Indinavir 800 mg 3 times/day was given for four doses on days 1 and 2. Silymarin 160 mg 3 times/day was given on days 3-15. On day 16 and for one dose on day 17, both drugs were given at the same dosages. Measurements and Main Results. Indinavir's pharmacokinetic parameters were evaluated at steady state both before and after administration of 14 days of silymarin. Blood samples were collected -0.25, 0.5, 1, 2, 3, 4, and 5 hours after indinavir dosing and assayed by high-performance liquid chromatography. The final pharmacokinetic model had first-order absorption after a lag time, and two compartments with first-order elimination from the central compartment. When given alone and combined with silymarin, respectively, the geometric mean (95% confidence interval [CI]) steady-state indinavir area under the plasma concentration-time curve was 20.7 hr.mg/L (15.3-28.2 hr.mg/L) and 19.4 hr.mg/L (15.8-23.6 hr.mg/L) and the trough plasma concentration was 0.340 mg/L (0.232-0.497 mg/L) and 0.232 mg/L (0.129-0.419 mg/L). Conclusion. Silymarin has no apparent effect on indinavir plasma concentrations.
引用
收藏
页码:866 / 870
页数:5
相关论文
共 25 条
[1]   Position paper on therapeutic drug monitoring of antiretroviral agents [J].
Acosta, EP ;
Gerber, JG .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) :825-834
[2]  
Bonacini Maurizio, 2002, AIDS Read, V12, P19
[3]  
BURGER DM, 2001, 2 INT WORKSH CLIN PH
[4]  
Choo EF, 2000, DRUG METAB DISPOS, V28, P655
[5]   PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS [J].
DARGENIO, DZ ;
SCHUMITZKY, A .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02) :115-134
[6]  
DARGENIO DZ, 1997, ADAPT 2 USER GUIDE R
[7]   Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin [J].
Dehmlow, C ;
Erhard, J ;
deGroot, H .
HEPATOLOGY, 1996, 23 (04) :749-754
[8]  
DIAZANI F, 1994, AIDS RES HUM RETROV, V10, P1471
[9]   HUMAN-IMMUNODEFICIENCY-VIRUS I-INDUCED EXPRESSION OF P-GLYCOPROTEIN [J].
GOLLAPUDI, S ;
GUPTA, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 171 (03) :1002-1007
[10]   P-GLYCOPROTEIN (MDR-1 GENE-PRODUCT) IN CELLS OF THE IMMUNE-SYSTEM - ITS POSSIBLE PHYSIOLOGICAL-ROLE AND ALTERATION IN AGING AND HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) INFECTION [J].
GUPTA, S ;
GOLLAPUDI, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1993, 13 (05) :289-301